Overview Post Marketing Surveillance Study of Biphasic Insulin Aspart 30 Status: Completed Trial end date: 2007-02-01 Target enrollment: Participant gender: Summary This study is conducted in Asia. The aim of this study is to review the safety and efficacy of biphasic insulin aspart 30 in post-marketing use. Details Lead Sponsor: Novo Nordisk A/STreatments: Biphasic InsulinsInsulinInsulin AspartInsulin aspart, insulin aspart protamine drug combination 30:70Insulin degludec, insulin aspart drug combinationInsulin, Globin ZincInsulin, IsophaneInsulin, Long-Acting